MUC1 and systemic sclerosis: Despite the fact that baseline KL-6 levels or their single measurement during the follow-up period cannot predict poor prognosis, KL-6 kinetic changes may be helpful in monitoring disease progression in SSc, with a reported cut-off of >193 U/mL [101].